John E. Bishop - 30 Jan 2024 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)

Role
Chief Technology Officer
Signature
/s/ Jason Cavalier, Attorney-in-Fact
Issuer symbol
LYRA
Transactions as of
30 Jan 2024
Net transactions value
$0
Form type
4
Filing time
01 Feb 2024, 16:15:20 UTC
Previous filing
28 Feb 2023
Next filing
17 Oct 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYRA Stock Options Award $0 +200,000 $0.000000 200,000 30 Jan 2024 Common Stock 200,000 $4.58 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 30, 2024.